Sullivan & Cromwell replaces Kirkland as Teva’s adviser for proposed $43bn acquisition of Mylan
Sullivan & Cromwell, along with a host of US, Dutch and Israeli firms, is representing Teva Pharmaceuticals as it seeks to acquire rival Mylan for $43bn, having replaced Kirkland & Ellis as the company’s adviser. Sullivan & Cromwell is acting for Teva with a corporate team consisting of New York partners Joseph Frumkin and Krishna […]